Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 5,290 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Terminated Phase 2 Interventional Results available

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

NCT04639024
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
Interventions
ADCT-301
Drug
Lead sponsor
Gwynn Long, M.D.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection, Solid Cancers
Interventions
Diet Intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Leukemia, Lymphoma
Interventions
bispecific antibody 4G7xH22, sargramostim
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Tafasitamab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Acute Leukemia
Interventions
Three-Pronged Approach to Reduce Hospital Acquired Deconditioning
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Conditions
Leukemia
Interventions
sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
16 Years to 60 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
BL-M11D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 15 more
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
MP Diagnostics HTLV Blot 2.4
Diagnostic Test
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Vosaroxin
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Tampa, Florida • Indianapolis, Indiana • Baltimore, Maryland + 2 more
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
EPZ-5676
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Chicago, Illinois • New York, New York + 3 more
Conditions
Leukemia
Interventions
Etoposide, Total Body Irradiation, Rituximab
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia
Interventions
Nipent, Cytoxan, Rituxan
Drug
Lead sponsor
East Valley Hematology and Oncology Medical Group
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
52
States / cities
Muscle Shoals, Alabama • Burbank, California • Concord, California + 44 more
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
chlorambucil, tablets, ofatumumab (GSK1841157) infusion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
30
States / cities
Sedona, Arizona • Tucson, Arizona • Murrieta, California + 25 more
Conditions
Chronic Myeloid Leukemia
Interventions
Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Conditions
Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions
CD8 Depleted Donor Lymphocyte
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Wilmington, North Carolina